Based on the recent IRIS-A trial presented at ASCO 2026, would adjuvant capecitabine plus trastuzumab be a reasonable consideration for a premenopausal patient with a unifocal, microinvasive (0.7 mm), ER/PR-positive, HER2-positive invasive ductal carcinoma (pT1miN0)?